Targeted Alpha Therapy in Oncology

Targeted alpha therapy harnesses the potent cytotoxicity of alpha-emitting radionuclides linked to tumour-specific carriers to deliver a highly localised dose of radiation directly to cancer cells. By exploiting the short path length and high linear energy transfer of alpha particles, this modality achieves precise tumour cell eradication with minimal collateral damage to surrounding tissue. Recent advances in radiochemistry have yielded improved chelators and linker strategies that stabilise isotopes such as actinium-225 and bismuth-213 within complex biological environments. Optimised targeting vectors, including monoclonal antibodies and engineered proteins, have extended the clinical applicability of this approach to micrometastatic lesions and refractory disease. Ongoing developments in isotope production, dosimetric modelling and protein engineering promise to broaden the spectrum of malignancies amenable to therapy, offering a path towards personalised, highly effective treatments with manageable safety profiles.

Research from Nature Portfolio

A novel platform combining an eight-coordinate synthetic ligand with a mammalian protein scaffold has been devised to elucidate the coordination chemistry of long-lived actinium isotopes under physiological conditions. Detailed structural and solution studies have provided unprecedented insight into the binding geometry and stability of actinium complexes, guiding the design of next-generation chelators for 225Ac and informing rational improvements in radiopharmaceutical stability and in vivo performance.

Targeted Alpha Therapy in Oncology publication trend

The graph below shows the total number of articles in targeted alpha therapy in oncology across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha particle: a high-energy helium nucleus emitted during radioactive decay, characterised by high linear energy transfer and a short penetration range in tissue.

Linear energy transfer (LET): the amount of energy deposited per unit length of particle track, with high LET facilitating dense ionisation and efficient cell kill.

Chelator: a molecule that forms multiple bonds to a metal ion, stabilising radionuclides within bioconjugates to prevent premature release.

PEGylation: the attachment of polyethylene glycol chains to molecules to improve solubility, pharmacokinetics and reduce immunogenicity.

References

1. Actinium chelation and crystallization in a macromolecular scaffold. Nature Communications (2024).
2. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics (2024).
3. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. European Journal of Nuclear Medicine and Molecular Imaging (2014).
4. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics (2020).
5. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”. Pharmaceutics (2021).